1-3 of 3
Taylor Bucy, BA
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Proportion of Patients with FLT3 Positive AML Required to Enroll on Clinical Trials to Satisfy the Recruitment Needs of FLT3 Inhibitor Trials: Are We Running out of Patients?

Taylor Bucy, BA, John Zoscak, MS, Motomi Mori, PhD, Vinayak Prasad, MD, Uma Borate, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 713.
https://doi.org/10.1182/blood-2018-99-120142
Published: 2018
Journal Articles

A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML): Alliance Clinical Trials in Oncology (Alliance) Historical Patient Control

Alice S. Mims, MD, Jessica Kohlschmidt, PhD, Uma Borate, MD, Brianna Norris, BS, Taylor Bucy, BA, James S. Blachly, MD, Shelley Orwick, BS, Ann-Kathrin Eisfeld, MD, Dimitrios Papaioannou, MD, Deedra Nicolet, MS, Krzysztof Mrózek, MD PhD, Bhavana Bhatnagar, DO, Eytan M. Stein, MD, Richard M. Stone, MD, Jonathan E. Kolitz, MD, Eunice S. Wang, MD, Bayard L. Powell, MD, Amy Burd, PhD, Ross L. Levine, MD, Brian J. Druker, MD, Clara D. Bloomfield, MD, John C. Byrd, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1489.
https://doi.org/10.1182/blood-2018-99-116717
Published: 2018
Journal Articles

Factors Predicting Response and Resistance to Midostaurin in FLT3 Positive and FLT3 Negative AML in 483 Primary AML Patient Samples

Kevin Watanabe-Smith, PhD, Mara Rosenberg, BS, Taylor Bucy, BA, Jeffrey W. Tyner, PhD, Uma Borate, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 296.
https://doi.org/10.1182/blood.V130.Suppl_1.296.296
Published: 2017